BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 33593882)

  • 21. Gene and protein expression profiles of JAK-STAT signalling pathway in the developing brain of the Ts1Cje down syndrome mouse model.
    Lee HC; Md Yusof HH; Leong MP; Zainal Abidin S; Seth EA; Hewitt CA; Vidyadaran S; Nordin N; Scott HS; Cheah PS; Ling KH
    Int J Neurosci; 2019 Sep; 129(9):871-881. PubMed ID: 30775947
    [No Abstract]   [Full Text] [Related]  

  • 22. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.
    Rampal R; Al-Shahrour F; Abdel-Wahab O; Patel JP; Brunel JP; Mermel CH; Bass AJ; Pretz J; Ahn J; Hricik T; Kilpivaara O; Wadleigh M; Busque L; Gilliland DG; Golub TR; Ebert BL; Levine RL
    Blood; 2014 May; 123(22):e123-33. PubMed ID: 24740812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential.
    Tzeng HT; Chyuan IT; Lai JH
    Biochem Pharmacol; 2021 Nov; 193():114760. PubMed ID: 34492272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors.
    Porosnicu M; Quinson AM; Crossley K; Luecke S; Lauer UM
    Future Oncol; 2022 Aug; 18(24):2627-2638. PubMed ID: 35699077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of JAK/STAT pathway regulators--insights from RNAi screens.
    Müller P; Boutros M; Zeidler MP
    Semin Cell Dev Biol; 2008 Aug; 19(4):360-9. PubMed ID: 18586112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteasome α6 Subunit Negatively Regulates the JAK/STAT Pathway and Blood Cell Activation in
    Järvelä-Stölting M; Vesala L; Maasdorp MK; Ciantar J; Rämet M; Valanne S
    Front Immunol; 2021; 12():729631. PubMed ID: 35003057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delivery of Tapasin-modified CTL epitope peptide via cytoplasmic transduction peptide induces CTLs by JAK/STAT signaling pathway in vivo.
    Wu S; Chen X; Tang Y; Zhang Y; Li D; Chen J; Wang J; Tang Z; Zang G; Yu Y
    Acta Biochim Biophys Sin (Shanghai); 2018 Feb; 50(2):181-190. PubMed ID: 29340620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vesicular stomatitis virus variants selectively infect and kill human melanomas but not normal melanocytes.
    Wollmann G; Davis JN; Bosenberg MW; van den Pol AN
    J Virol; 2013 Jun; 87(12):6644-59. PubMed ID: 23552414
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.
    Galivo F; Diaz RM; Thanarajasingam U; Jevremovic D; Wongthida P; Thompson J; Kottke T; Barber GN; Melcher A; Vile RG
    Hum Gene Ther; 2010 Apr; 21(4):439-50. PubMed ID: 19922169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Janus Kinase in the JAK/STAT signaling pathway from Litopenaeus vannamei is involved in antiviral immune response.
    Song X; Zhang Z; Wang S; Li H; Zuo H; Xu X; Weng S; He J; Li C
    Fish Shellfish Immunol; 2015 Jun; 44(2):662-73. PubMed ID: 25839969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus.
    Felt SA; Droby GN; Grdzelishvili VZ
    J Virol; 2017 Aug; 91(16):. PubMed ID: 28566376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling.
    Girardi T; Vereecke S; Sulima SO; Khan Y; Fancello L; Briggs JW; Schwab C; de Beeck JO; Verbeeck J; Royaert J; Geerdens E; Vicente C; Bornschein S; Harrison CJ; Meijerink JP; Cools J; Dinman JD; Kampen KR; De Keersmaecker K
    Leukemia; 2018 Mar; 32(3):809-819. PubMed ID: 28744013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. JAK/STAT signaling regulates the Harmonia axyridis leg regeneration by coordinating cell proliferation.
    Zhou H; Wang W; Yan S; Zhang J; Wang D; Shen J
    Dev Biol; 2022 Mar; 483():98-106. PubMed ID: 34999052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in genome-wide RNAi cellular screens: a case study using the Drosophila JAK/STAT pathway.
    Fisher KH; Wright VM; Taylor A; Zeidler MP; Brown S
    BMC Genomics; 2012 Sep; 13():506. PubMed ID: 23006893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhancer of Polycomb and the Tip60 complex repress hematological tumor initiation by negatively regulating JAK/STAT pathway activity.
    Bailetti AA; Negrón-Piñeiro LJ; Dhruva V; Harsh S; Lu S; Bosula A; Bach EA
    Dis Model Mech; 2019 May; 12(5):. PubMed ID: 31072879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
    Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
    J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The oncolytic virus VT09X optimizes immune checkpoint therapy in low immunogenic melanoma.
    Zhu W; Lv J; Xie X; Tian C; Liu J; Zhou H; Sun C; Li J; Hu Z; Li X
    Immunol Lett; 2022 Jan; 241():15-22. PubMed ID: 34774916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma.
    Galivo F; Diaz RM; Wongthida P; Thompson J; Kottke T; Barber G; Melcher A; Vile R
    Gene Ther; 2010 Feb; 17(2):158-70. PubMed ID: 20016540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screening.
    Zhong Y; Le H; Zhang X; Dai Y; Guo F; Ran X; Hu G; Xie Q; Wang D; Cai Y
    J Hematol Oncol; 2024 May; 17(1):36. PubMed ID: 38783389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
    Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
    Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.